OXIS International, Inc. Finalizes First Commercial Sale of L-Ergothioneine to Minitube of America

FOSTER CITY, Calif.--(BUSINESS WIRE)--Oxis International Inc. (OTCBB: OXIS), a biopharmaceutical company focused on commercializing predictive biomarkers, clinical assays and nutraceutical and therapeutic products, announced today that it has received its first commercial purchase order for L-Ergothioneine (ERGO), its proprietary, lead antioxidant product. ERGO is protected by United States and foreign patents, claiming the only known method of synthesizing this potent antioxidant in commercial quantities. In a recent joint research project with Minitube of America (MINITUBE), located in Madison WI, and Golden Gourmet Mushrooms (GGM), San Marcos CA, ERGO was shown to exert a significant protective effect on sperm cells obtained from horses and boars and significantly increased sperm cell viability. These positive findings will be explored through subsequent joint, equine, porcine, bovine, and canine clinical fertility research projects.